ABSTRACT A series of monoclonal antibodies have been raised against a preparation of the factor VIII/von Willebrand factor molecule. Ofthe seven hybridomas showing specific activity against the factor VIII molecule in a solid-phase radioimmunoassay, three (F4.55, F4.77, and F4.264) have been shown to partially inhibit ristocetin-induced platelet aggregation and two (F4.115 and F4.415) inhibit the antihemophilic activity of the factor VIII molecule. An additional monoclonal antibody was directed against a contaminant of the factor VIII preparation and is an antifibrinogen antibody.
The human factor VIII/von Willebrand protein (F.VIII/vWF) is a complex plasma glycoprotein associated with two different biological activities (1, 2): a procoagulant activity (VIII:C) and a von Willebrand activity (VIIIR:WF). The former is implicated in platelet adhesion to the vascular subendothelium and is measured by platelet aggregation in the presence of ristocetin (3) . The procoagulant activity (antihemophilic factor) is measured by coagulation time correction of plasma from a severe hemophilic patient (4) .
Little is known of the biochemistry of VIII:C. VIIIR:WF has been identified as a high molecular weight glycoprotein that circulates in the plasma as multimers ofa single Mr 220,000 subunit. The high molecular weight polymers found vary in Mr from several hundred thousand to several million and can be considered the native form of the molecule in plasma (5) . The relationship of biochemical structure of the F. VIII/vWF molecule to the biological activities remains controversial. It is still unclear whether the two activities are carried by two different sites on a single molecule (6) or by two or more distinct molecules, the intact molecule thus being a heteropolymer (2) .
Biochemical studies have been hampered by the low concentration of F.VIII/vWF in the plasma (5-10 ,Ag/ml) and by the extreme lability of the F.VIII/vWF-associated biological activities. This has rendered extremely difficult the recovery ofthe native molecule after purification. The F.VIII/vWF molecule has thus remained one of the less-well-characterized, factors involved in the hemostatic process. Attempts at an immunological characterization ofthe F.VIII/ vWF molecule have been limited. Two basic types of antisera exist. The first class, heteroantisera identifying the factor VIIIrelated antigen (VIIIR:Ag) are capable of neutralizing VIII:C and can neutralize or precipitate VIIIR:WF. Precipitating antisera recognize a single protein from normal plasma, presumably responsible for VIII:C and VIIIR:WF biological activities (7) . The second class, alloantisera, arise either spontaneously or after transfusion of hemophilic A patients and identify the VIIIC:Ag. These VIII:C-neutralizing antisera are not precipitating (8) . As with other proteins, antigenic reactivity and biologic activity do not necessarily correspond.
Given the limitations of these existing antisera and the potential represented by immunochemical and immunological techniques for probing the F.VIII/vWF molecule, the isolation and use of monoclonal antibodies seemed likely to be fruitful. One such report has appeared recently (9) . We report here the establishment of seven hybridoma cell lines from a fusion involving spleen cells from a mouse immunized with a factor VIII concentrate. The seven hybridoma cell lines secrete antibodies active against the F.VIII/vWF protein. Three ofthem partially inhibit ristocetin-induced platelet aggregation and may be directed against an antigenic site(s) involved in von Willebrand activity. Two others inhibit the coagulation process and are directed against the antihemophilic activity of factor VIII. An eighth hybridoma isolated from this fusion series has been shown to secrete a monoclonal antibody directed against fibrinogen, a contaminant of all preparations of F.VIII/vWF protein.
MATERIALS AND METHODS
Commercial Factor VIII Preparation. "Actif VIII high-purity concentrate batch 9C 24 004" was kindly provided by Merieux Laboratories. It contained VIIIR:Ag at 128 units (U)/ ml, VIII:C at 28 U/ml, and VIIIR:WF at 33 U/ml.
Highly Purified Factor VIII. This was prepared from the commercial preparation. Lyophilized concentrates dissolved (20 mg of protein per ml) in 0.15 M Tris/NaCl, pH 7.4, were chromatographed on a Sepharose CL-2B column in this buffer plus aprotinin at 10 U/ml. Fractions containing VIIIR:Ag were pooled and concentrated by dialysis against polyethylene glycol.
Such preparations having an A2N of0.2-0.3 contained VIIIR:Ag at 20-40 U/ml, VIIIR:WF at 20-40 U/ml, and VIII:C at 15-25 U/ml. Semipurified Factor VIII Fractions. These were prepared either directly from human citrated plasma by chromatography on Sepharose CL-2B in 0.15 M Tris/NaCl, pH 7.4, or by such chromatography after initial treatment by adsorption on aluminium hydroxide gel, cryoprecipitation at -80°C, thawing at 40C, centrifugation, and resuspension in the chromatography buffer. The void volume fractions were collected and concentrated. "Direct" preparations contained 4-8 U of VIIIR:Ag per ml, 2-4 U of VIII:C per ml, and 4-8 U of VIIIR:WF per ml. Radioimmunoassay. The plates were first washed with PJ NaCl. They were then incubated with 50 ul of culture supernatant or ascitic fluid for 1 hr at 370C. After three PJNaCl washes, 50 p.l of a "WI-labeled goat anti-mouse Ig antiserum (100,000-150,000 cpm/50 g1) was added and the plates were incubated for 1 hr at 37C. l"I labeling ofthis developing serum was carried out by using the Iodogen reaction (18) . The plates were then rinsed three times with PJNaCl, and the radioactivity of the wells was measured by using an LKB gamma counter.
Negative radioimmunoassay controls included the activity of the supernatants on PJNaC/albumin-coated plastic and the activity of X63 culture supernatants or X63 ascites on coated plates. In some tests, this was complemented by-the use of irrelevant monoclonal ascites: BBF 39-27 (anti-Friend virus), donated by F. Plata, or Ab 1.41 (anti-HLA-DR), a gift of D. J. Charron (19) . Binding of the X63, BBF 39-27, and Ab. 1.41 ascites was identical, on all preparations used. The levels ofnonspecific binding are indicated in Results. Binding greater.than 3 times that of the nonspecific controls was considered to be positive. "Titer" refers to the greatest dilution at which a serum or supernatant remained positive. The quantity of factor VIII attaching per well was estimated as 20 pug by using a "MI-labeled factor VIII preparation.
hihibition of VIIIR:WF Activity. Inhibition of VIIIR:WF activity was tested in a system of ristocetin-induced platelet aggregation. Platelet-rich plasma was adjusted in homologous platelet poor plasma to a concentration of400,000 platelets per t1. and 0.2 ml of it was incubated for 5 min at 37C with 0.1 ml of buffer or ascitic fluids in an aggregometer cuvette, then agitated at 1100 rpm with 0.1 ml ofa ristocetin solution (final concentration, 1 mg/ml). The maximum of the aggregation curve was calculated for the control plasma and inhibition was calculated as percentage of it.
Inhibition of the VIII:C Activity. Inhibition of VIII:C, as a screening test, was performed in a partial thromboplastin time system using plasma from a severe hemophilic as substrate. Ascitic fluid or buffer was incubated with equal volumes of a standard plasma pool (1 U of VIII:C per ml) for 1 hr at 37°C; 0.1 ml of this mixture was then added to 0.1 ml of hemophilic plasma, 0.1 ml of partial thromboplastin, and 0.1 ml of a kaolin suspension and incubated for 5 min at 37C. The mixture was then recalcified (0.1 ml of 0.025 M calcium chloride) and the coagulation time was measured.
Titration of Anti-VEII:C Activity. Standard pool plasma (1 U of VIII:C per ml) was incubated with buffer or dilutions ofascitic fluid for 2 hr at 37°C. Residual VIII:C was estimated by using the partial thromboplastin time system. Ascitic fluid dilutions were tested until 100% VIII:C activity was recovered.
At least two unrelated ascitic fluids were always included as controls in addition to the culture medium itself.
Identification of the Ig Subclasses Secreted by the Various Hybridomas. -Culture supernatants concentrated on polyethylene glycol 20,000 were tested in a double-immunodiffusion system with specific rabbit antisera to mouse Ig subclasses (Nordic). The latter were verified by using purified Ig standards (Bionetics).
Ascites Production. Pristane-Frimed (BALB/c X C57B1/ 6)F1 mice were injected with 10 All the ascites except F4.77 were positive on the semipurified factor VIII with titers varying from 1:40 to 1:10,000 (Table 1 and Fig. 1 ). On highly purified factor VIII preparation, all, including F4.77, were positive. Ascites F4.6, F4.55, F4.77, F4.115, and F4.118 all had increased titers on the purified preparation, suggesting that they were indeed directed against the factor VIII itself and not a minor contaminant. The ascites that gave the highest titers had titers greater than 1:10,000. Regardless of titer considerations, some of the ascites showed qualitatively different binding profiles-for example, in Fig. 1A for ascites F4.415 and F4.115.
Hybridomas were tested against human fibrinogen, human plasma fibronectin, and total human immunoglobulins. All were negative on fibronectin and immunoglobulin preparations. Against fibrinogen, six of the hybridomas were completely negative and two showed some activity: F4.115 had a low titer (see also Fig. 1C ) and F4.177 showed binding to fibrinogen equivalent to that shown on factor VIII preparations. Because the titer ofF4.115 was much lower on fibrinogen than on highly purified factor VIII preparation, it seems likely that the activity of this hybridoma was directed against the factor VIII molecule(s) itself, the low activity on the fibrinogen preparation being due to minor contamination by factor VIII molecules or to some crossreacting antigen. If the first hypothesis is correct, only a restricted range of factor VIII antigenic determinants can be contaminating such fibrinogen preparations because otherwise the other hybridomas would have reacted with the preparation. Hybridoma F4.177, on the other hand, potentially is an antifibrinogen antibody.
This interpretation of both F4.115 and F4.177 activity on fibrinogen preparations is supported by experiments with factor VIII preparations from normal human plasma and plasma ofan afibrinogenemic patient (Fig. 2) . Binding of the ascites fluid to factor VIII prepared from normal plasma was more or less equivalent to that observed on a semipurified factor VIII preparation obtained after cryoprecipitation. Binding on the factor VIII preparation obtained from the afibrinogenemic patient was quite different. F4.177 was clearly negative, indirect proofthat F4.177 probably is directed against the fibrinogen molecule itself. All the other ascites, and in particular F4.115, were positive on the fibrinogen-free preparation and they could be separated into two groups: (a) F4.55, F4.264, and F4.415, having equivalent binding on fibrinogen-free and normal preparations; and (b) F4.6, F4.77, F4.115, and F4.118, having increased activity on the fibrinogen-free factor VIII preparation.
The interpretation of these results must consider the type of radioimmunoassay used, and several alternative explanations can be envisaged. One possible interpretation is that the absence of fibrinogen increases the accessibility of the factor VIII molecule in the preparation for the plastic matrix, thus allowing an increase in antigenic density ofthose antigens recognized by the hybridomas in the second group. According to this interpretation, antigenic sites (epitopes) recognized by the first hybridoma group would already be present in excess and their binding would not be modified by the absence of fibrinogen. Such epitopes might be more repetitively distributed on the (Table 2) . Incubation ofthese ascites with normal platelet-rich plasma produced partial inhibition ofristocetin-induced platelet aggregation. Fig. 3 illustrates the differences seen between the control (unrelated ascites X63) and the F4.55 positive ascitic fluid and the dose-response effect. Inhibition of aggregation was 58% at the 1:10 dilution, 46% at, 1:40, and 30% at 1:80. Inhibition by clone F4.264 occurred only for the 1:5 dilution; with clone F4.77, 50% inhibition was observed at.the 1:5 dilution and persisted to the 1:40 dilution. The inhibition titers for aggregation seem somewhat lower than those noted in the radioimmunoassay, suggesting that possibly a large number of antigenic sites must be occupied before aggregation inhibition can be observed. Support for this idea comes from mixing experiments such as that shown in Fig. 3B (Table 2) . They showed dissimilar VIII:C neutralizing curves when neutralization was studied as a func- (Fig. 1B ) cannot be taken automatically to indicate a low affinity for the factor VIII molecules and therefore their lack of suitability for further study.
As expected, against a molecule as large and as complex as the F.VIII/vWF, a series of hybridomas, of which at least several are certainly directed against different antigenic sites, have been isolated. Fig. 2 illustrates this effect and also demonstrates how, independent oftheir titer, the hybridomas divide into two different categories depending on whether their binding is similar on factor VIII preparations from normal and afibrinogenemic donors or whether their binding is markedly superior on the latter type of preparation. It is interesting to note that the hybridomas active in the biological activity tests do not fall into either of these two groups. It seems clear that the three hybridomas inhibitory against ristocetin-induced aggregation are directed against different antigenic sites because additivity in their inhibitory action is seen (Fig. 3B ). There are no indications that F4.415 and F4.115 hybridomas recognize different antigenic sites but they clearly behave differently in the coagulation inhibition tests (Fig. 4) .
Inactivation patterns such as those described above have been noted for hemophiliac antibodies against VIII:C (20), the different time course patterns ofVIII:C inactivation depending on the patient considered. Inactivation patterns such as those described for hemophiliac antibodies therefore can be obtained with monoclonal antibodies from hybridoma cell lines.
The results of the biological activity tests, like those of the radioimmunoassay, have been expressed as a function of titer because normalization of these values for total proteins or for total immunoglobulin content ofthe ascites fluids does not provide a better basis for comparison of the specific activities ofthe hybridomas between themselves or with the classical allogeneic or autologous anti-VIIIR:WF or anti-VIII:C antisera.
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